FFA
DMAC icon

Farther Finance Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Farther Finance Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8K Hold
4,235
– – ﹤0.01% 3670
2026
Q1 		$27.2K Hold
4,235
– – ﹤0.01% 3439
2025
Q4 		$33.7K Buy
+4,235
New +$31.7K ﹤0.01% 3079

Other funds holding DMAC

MW
Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Farther Finance Advisors's DMAC Position: Q2 2026 in Review

Farther Finance Advisors held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 4,235 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

Farther Finance Advisors first reported a position in DMAC in Q4 2025 and has held it in 3 quarters since. The position peaked at $33.7K in Q4 2025. 6 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Farther Finance Advisors held 4,235 shares of DiaMedica Therapeutics worth $29.8K as of Q2 2026.
  • Farther Finance Advisors left its DiaMedica Therapeutics share count unchanged in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3670 holding.
  • Farther Finance Advisors first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Farther Finance Advisors's DiaMedica Therapeutics position peaked at $33.7K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.